These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

655 related items for PubMed ID: 32673798

  • 1. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
    Mahjoubin-Tehran M, De Vincentis A, Mikhailidis DP, Atkin SL, Mantzoros CS, Jamialahmadi T, Sahebkar A.
    Mol Metab; 2021 Aug; 50():101049. PubMed ID: 32673798
    [Abstract] [Full Text] [Related]

  • 2. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
    Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, Sattar N, Fraser A, Waugh N.
    Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
    [Abstract] [Full Text] [Related]

  • 3. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
    Blazina I, Selph S.
    Syst Rev; 2019 Nov 29; 8(1):295. PubMed ID: 31783920
    [Abstract] [Full Text] [Related]

  • 4. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
    Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA, Nonalcoholic Steatohepatitis Clinical Research Network.
    Hepatology; 2019 Aug 29; 70(2):522-531. PubMed ID: 30549292
    [Abstract] [Full Text] [Related]

  • 5. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, Mantzoros CS.
    Curr Vasc Pharmacol; 2020 Aug 29; 18(2):172-181. PubMed ID: 30961499
    [Abstract] [Full Text] [Related]

  • 6. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Fang L, Li J, Zeng H, Liu J.
    Prim Care Diabetes; 2024 Jun 29; 18(3):268-276. PubMed ID: 38555202
    [Abstract] [Full Text] [Related]

  • 7. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
    Sanyal AJ, Williams SA, Lavine JE, Neuschwander-Tetri BA, Alexander L, Ostroff R, Biegel H, Kowdley KV, Chalasani N, Dasarathy S, Diehl AM, Loomba R, Hameed B, Behling C, Kleiner DE, Karpen SJ, Williams J, Jia Y, Yates KP, Tonascia J.
    J Hepatol; 2023 Apr 29; 78(4):693-703. PubMed ID: 36528237
    [Abstract] [Full Text] [Related]

  • 8. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
    Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, Kohli A, Sarin S, Caldwell SH, Alkhouri N, Shiffman ML, Camargo M, Li G, Kersey K, Jia C, Zhu Y, Djedjos CS, Subramanian GM, Myers RP, Gunn N, Sheikh A, Anstee QM, Romero-Gomez M, Trauner M, Goodman Z, Lawitz EJ, Younossi Z, STELLAR-3, STELLAR-4 Investigators.
    J Hepatol; 2020 Jul 29; 73(1):26-39. PubMed ID: 32147362
    [Abstract] [Full Text] [Related]

  • 9. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C.
    Metabolism; 2017 Jun 29; 71():17-32. PubMed ID: 28521870
    [Abstract] [Full Text] [Related]

  • 10. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
    Said A, Akhter A.
    Ann Hepatol; 2017 Jun 29; 16(4):538-547. PubMed ID: 28611274
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G.
    Diabetes Metab; 2020 Nov 29; 46(6):427-441. PubMed ID: 31923578
    [Abstract] [Full Text] [Related]

  • 12. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A, Shasthry SM, Agarwal A, Bihari C, Jain P, Jindal A, Sarin S.
    APMIS; 2017 Nov 29; 125(11):962-973. PubMed ID: 29076589
    [Abstract] [Full Text] [Related]

  • 13. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review.
    Zachou M, Flevari P, Nasiri-Ansari N, Varytimiadis C, Kalaitzakis E, Kassi E, Androutsakos T.
    Eur J Clin Pharmacol; 2024 Jan 29; 80(1):127-150. PubMed ID: 37938366
    [Abstract] [Full Text] [Related]

  • 14. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH.
    Majzoub AM, Nayfeh T, Barnard A, Munaganuru N, Dave S, Singh S, Murad MH, Loomba R.
    Aliment Pharmacol Ther; 2021 Oct 29; 54(7):880-889. PubMed ID: 34435378
    [Abstract] [Full Text] [Related]

  • 15. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.
    Eshraghian A.
    World J Gastroenterol; 2017 Nov 14; 23(42):7495-7504. PubMed ID: 29204050
    [Abstract] [Full Text] [Related]

  • 16. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
    Imprialos K, Stavropoulos K, Bouloukou S, Kerpiniotis G, Karagiannis A, Doumas M.
    Curr Vasc Pharmacol; 2018 Nov 14; 16(3):276-288. PubMed ID: 28676020
    [Abstract] [Full Text] [Related]

  • 17. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.
    Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L.
    Aliment Pharmacol Ther; 2014 Jan 14; 39(1):3-14. PubMed ID: 24206433
    [Abstract] [Full Text] [Related]

  • 18. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG, Boutari C, Stavropoulos K, Anagnostis P, Imprialos KP, Doumas M, Karagiannis A.
    Curr Vasc Pharmacol; 2018 Jan 14; 16(3):246-253. PubMed ID: 28676019
    [Abstract] [Full Text] [Related]

  • 19. Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin.
    Gawrieh S, Harlow KE, Pike F, Yates KP, Wilson LA, Cummings OW, Rosenberg WM, Chalasani N, Molleston JP.
    J Pediatr; 2021 Dec 14; 239():161-167.e5. PubMed ID: 34400208
    [Abstract] [Full Text] [Related]

  • 20. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
    Caldwell S.
    Clin Mol Hepatol; 2017 Jun 14; 23(2):103-108. PubMed ID: 28494529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.